UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1362-4
Program Prior Authorization/Notification
Medication Verquvo® (vericiguat)
P&T Approval Date 7/2021, 9/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background
Verquvo (vericiguat) is indicated to reduce the risk of cardiovascular death and heart failure (HF)
hospitalization following a hospitalization for heart failure or the need for outpatient IV diuretics, in
adults with symptomatic chronic HF and ejection fraction less than 45%. Verquvo has a boxed
warning for embryo-fetal toxicity and should not be used during pregnancy.
2. Coverage Criteriaa
A. Initial Authorization
1. Verquvo will be approved based on all the following criteria:
a. Diagnosis of symptomatic heart failure
-AND-
b. Ejection fraction is less than 45 percent
-AND-
c. Heart failure is classified as one of the following:
(1) New York Heart Association Class II
(2) New York Heart Association Class III
(3) New York Heart Association Class IV
-AND-
d. One of the following:
(1) Hospitalization for heart failure within the past six months
(2) Outpatient IV diuretics for heart failure within the past three months
Authorization will be issued for 12 months
B. Reauthorization
1. Verquvo will be approved based on the following criterion:
© 2024 UnitedHealthcare Services, Inc.
1
a. Documentation of a positive clinical response to Verquvo therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan
coverage may also impact coverage criteria. Other policies and utilization management programs may
apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Verquvo [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; July 2023.
Program Prior Authorization/Notification – Verquvo
Change Control
Date Change
7/2021 New program
9/2022 Annual review. Updated references, added reauthorization criteria,
added state mandate footnote.
11/2023 Annual review. Updated references.
11/2024 Annual review with no changes.
© 2024 UnitedHealthcare Services, Inc.
2